INT262348

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 2006
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 12
Total Number 13
Disease Relevance 12.64
Pain Relevance 2.08

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Lgsn (Rattus norvegicus)
Pain Link Frequency Relevance Heat
antiepileptic Drug 221 99.54 Very High Very High Very High
Lamotrigine 102 99.28 Very High Very High Very High
carbamazepine 57 98.32 Very High Very High Very High
withdrawal 21 96.00 Very High Very High Very High
anticonvulsant 40 95.76 Very High Very High Very High
headache 18 95.16 Very High Very High Very High
tolerance 16 94.72 High High
anesthesia 15 94.24 High High
gABA 94 89.68 High High
nMDA receptor antagonist 5 88.16 High High
Disease Link Frequency Relevance Heat
Syndrome 878 100.00 Very High Very High Very High
Epilepsy 554 100.00 Very High Very High Very High
Convulsion 834 99.88 Very High Very High Very High
Syncope 87 99.48 Very High Very High Very High
Absence Epilepsy 28 99.48 Very High Very High Very High
Volume Depletion And Dehydration 6 98.08 Very High Very High Very High
Partial Seizures 57 97.78 Very High Very High Very High
Fatigue 24 96.76 Very High Very High Very High
Overdose 5 96.08 Very High Very High Very High
Dizziness 15 95.92 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Other randomized controlled trials in LGS
Gene_expression (trials) of LGS associated with syndrome
1) Confidence 0.58 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2654531 Disease Relevance 0.99 Pain Relevance 0.19
However, a Cochrane review has concluded that no single AED could be considered highly efficacious for LGS (Hancock and Cross 2003).
Gene_expression (efficacious) of LGS associated with syndrome
2) Confidence 0.58 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2654531 Disease Relevance 1.27 Pain Relevance 0.15
A patientÂ’s quality of life is very poor, with drop attacks being the most troubling presentation of LGS.
Gene_expression (presentation) of LGS associated with syndrome and syncope
3) Confidence 0.58 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2951747 Disease Relevance 1.88 Pain Relevance 0.08
Only a few AEDs have been shown to be effective for LGS.8 Even with AED polytherapy, the long-term prognosis is poor, with a persistence of epilepsy in more than 75% of patients.9 This incomplete seizure control often results in significant lifetime health care costs for the patient.10
Gene_expression (effective) of LGS associated with epilepsy, convulsion, syndrome and antiepileptic drug
4) Confidence 0.58 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2951747 Disease Relevance 1.89 Pain Relevance 0.10
However, in practice, they are still widely prescribed with the specific risk in LGS of precipitating tonic SE (Dimario and Clancy 1988).


Gene_expression (prescribed) of LGS associated with epilepsy and syndrome
5) Confidence 0.46 Published 2008 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2646636 Disease Relevance 0.72 Pain Relevance 0.38
However, this drug could be promising in LGS because of its potential broad spectrum of action, in spite of probable drug-drug interactions.
Gene_expression (promising) of LGS associated with syndrome
6) Confidence 0.46 Published 2008 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2646636 Disease Relevance 0.67 Pain Relevance 0.06
At the present time, there is no ongoing study of neuroprotection in LGS.


Gene_expression (neuroprotection) of LGS associated with syndrome
7) Confidence 0.46 Published 2008 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2646636 Disease Relevance 0.87 Pain Relevance 0.20
Four AEDs (FBM, LTG, TPM and RUF) have been officially licensed for LGS after demonstrating significant efficacy in randomized, double-blind, placebo controlled studies.
Gene_expression (licensed) of LGS associated with syndrome, lamotrigine and antiepileptic drug
8) Confidence 0.46 Published 2008 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2646636 Disease Relevance 0.98 Pain Relevance 0.21
STP was first identified in 1978 with clinical trials starting in the 1980s in all forms of epileptic syndromes, including LGS in which it was used in combination with CBZ (Tran et al 1996).
Gene_expression (identified) of LGS associated with epilepsy, syndrome and carbamazepine
9) Confidence 0.46 Published 2008 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2646636 Disease Relevance 0.94 Pain Relevance 0.21
The exorbital LGs were excised after the rats were given a lethal dose of sodium pentobarbital.
Gene_expression (excised) of LGs
10) Confidence 0.36 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2886053 Disease Relevance 0.23 Pain Relevance 0
Both exorbital LGs were excised and cut into fragments of 0.5 to 1 mm with a scalpel blade.
Gene_expression (excised) of LGs
11) Confidence 0.36 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2886053 Disease Relevance 0.22 Pain Relevance 0.45
For the hematoxylin and eosin staining, the LGs were fixed in 10% formalin.
Gene_expression (fixed) of LGs
12) Confidence 0.36 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2886053 Disease Relevance 0.32 Pain Relevance 0.05
In this study, partial seizures, generalized seizures, drop attacks (ie, atonic seizures), atypical absence seizures, myoclonic seizures, and LGS were shown to be effectively controlled with zonisamide.
Gene_expression (controlled) of LGS associated with convulsion, syndrome, absence epilepsy, syncope and partial seizures
13) Confidence 0.16 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671817 Disease Relevance 1.68 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox